Zevalin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancement of monoclonal antibody development, expansion of nuclear medicine capabilities, increased diagnosis of non-hodgkin lymphoma, early clinical use of radiolabeled therapies, improved oncology imaging technologies.

The growth in the forecast period can be attributed to increasing investments in targeted cancer therapies, growing demand for personalized oncology solutions, expansion of radiopharmaceutical infrastructure, rising focus on treatment efficacy with reduced toxicity, continued innovation in antibody-based cancer treatments. Major trends in the forecast period include increasing adoption of targeted radioimmunotherapy, growing use of precision oncology approaches, expansion of lymphoma-specific treatment protocols, enhanced integration of nuclear medicine infrastructure, rising focus on treatment selectivity.

The rising incidence of non-Hodgkin’s lymphoma is expected to drive growth in the Zevalin market. Non-Hodgkin lymphoma encompasses various blood cancers originating in lymphocytes that affect the lymphatic and immune systems. Its increasing incidence is linked to factors such as an aging population, higher exposure to risk factors like immunosuppression, environmental influences, and lifestyle changes. Zevalin is a monoclonal antibody that targets CD20, a protein found on B-cells commonly affected in non-Hodgkin’s lymphoma, delivering targeted radiation to destroy cancerous B-cells, shrink tumors, and improve remission rates. For example, in January 2024, the American Cancer Society reported that non-Hodgkin lymphoma accounts for roughly 4% of all new cancer cases in the U.S., with an estimated 80,620 new diagnoses, including 44,590 males and 36,030 females. Therefore, the rising incidence of non-Hodgkin’s lymphoma is driving the Zevalin market.

The growing geriatric population is also expected to support Zevalin market growth. The geriatric population, defined as individuals aged 65 and above, often requires specialized care due to age-related health challenges. This population is increasing because of longer life expectancy, declining fertility rates, and better access to healthcare. Zevalin provides a targeted and less invasive treatment option, reducing side effects and improving outcomes for older patients, thereby enhancing their quality of life. For instance, in July 2024, the UK House of Commons Library reported that the population aged 65 and older totaled 12.7 million in 2022 (19% of the population) and is projected to rise to 22.1 million (27% of the population) by 2072. Therefore, the growing geriatric population is fueling the Zevalin market.

Expansion in healthcare infrastructure is another factor driving Zevalin market growth. Healthcare infrastructure, which includes facilities, systems, equipment, and workforce, supports the delivery of medical services. Growth in this area is driven by an aging population, rising demand for quality healthcare, increased government investment, and technological advancements. Improved infrastructure enhances access to advanced cancer therapies, making Zevalin’s targeted radioimmunotherapy more impactful in patient care. For example, in May 2023, the American Health Care Association reported that the U.S. had 6,129 hospitals, up 0.591% from 6,093 hospitals the previous year. Therefore, growth in healthcare infrastructure is supporting the Zevalin market.

Major companies operating in the zevalin market are Acrotech Biopharma Inc.

North America was the largest region in the zevalin market in 2025. The regions covered in the zevalin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zevalin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zevalin market by increasing costs of imported radioisotopes, monoclonal antibody production materials, specialized shielding equipment, and nuclear medicine logistics services. Oncology centers in North America and Europe are most affected due to reliance on international radioisotope supply chains and specialized manufacturing inputs. These tariffs can increase therapy costs and limit treatment accessibility. However, they are also encouraging domestic radioisotope production, regional radiopharmaceutical manufacturing, and long-term investment in localized nuclear medicine infrastructure.

The zevalin market research report is one of a series of new reports that provides zevalin market statistics, including zevalin industry global market size, regional shares, competitors with a zevalin market share, detailed zevalin market segments, market trends and opportunities, and any further data you may need to thrive in the zevalin industry. This zevalin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zevalin (ibritumomab tiuxetan) is a radiolabeled monoclonal antibody therapy used to treat non-Hodgkin lymphoma (NHL). It combines an antibody with yttrium-90, a radioactive isotope, to specifically target and destroy cancerous B-cells, providing a focused treatment that limits damage to healthy tissues.

The main indications for Zevalin are relapsed or refractory low-grade non-Hodgkin lymphoma and previously untreated follicular non-Hodgkin lymphoma. Relapsed or refractory low-grade NHL refers to cases where the disease has returned after prior therapy or is resistant to standard treatments. Zevalin is available in formulations such as In-111 Zevalin and Y-90 Zevalin and is distributed through hospitals, specialty pharmacies, and online pharmacies. It is used by adult and geriatric patients.

The zevalin market consists of sales of injections, radiolabeled therapy kits, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.